Comment from Magnolia Health & Wellness
AnonymousOpposeIndividual
Summary: A clinic representative (commenting as an individual) opposes the FDA's decision to move specific peptides to Category 2 of the Bulk Drug Evaluation list. They argue that this move restricts access to beneficial medications for their patients and request that the FDA reconsider the decision based on the compounds' safety and health benefits.
The FDA's decision to move the peptides listed below to Category 2 of the Bulk Drug Evaluation list has posed tremendous harm to the patients of our clinic that depend on the benefits of these medications. According to the FDA, pending further evaluation, drug products compounded using these peptides are not eligible for pharmacy compounding. Our belief remains firm that these compounds are highly beneficial to patients, supported by available data that illustrates minimal safety risk as well as the extensive health benefits. Please reconsider this move as it will be detrimental to the health of many patients.